Evogene Ltd. Reports Q3 2024 Financial Results
Ticker: EVGN · Form: 6-K · Filed: Nov 21, 2024 · CIK: 1574565
Sentiment: neutral
Topics: earnings, financial-results, sec-filing
TL;DR
Evogene dropped its Q3 2024 earnings report today, check the 6-K for details.
AI Summary
Evogene Ltd. announced its financial results for the third quarter ended September 30, 2024, on November 21, 2024. The company, which operates in the agriculture chemicals sector, filed a Form 6-K report with the SEC to disclose these results. The filing includes a press release as Exhibit 99.1 detailing the financial performance for the period.
Why It Matters
This filing provides investors with an update on Evogene's financial health and performance for the third quarter of 2024, which is crucial for assessing the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial results filing and does not contain significant new risk factors.
Key Players & Entities
- Evogene Ltd. (company) — Registrant
- September 30, 2024 (date) — End of Q3 reporting period
- November 21, 2024 (date) — Date of announcement and filing
- Exhibit 99.1 (document) — Press release containing financial results
FAQ
What period do the financial results in this 6-K filing cover?
The financial results in this 6-K filing cover the third quarter ended September 30, 2024.
What is the main purpose of this Form 6-K filing?
The main purpose of this Form 6-K filing is to report the financial results of Evogene Ltd. for the third quarter ended September 30, 2024.
When did Evogene Ltd. announce its Q3 2024 financial results?
Evogene Ltd. announced its financial results for the third quarter ended September 30, 2024, on November 21, 2024.
Where can the press release announcing Evogene's Q3 2024 financial results be found?
The press release announcing Evogene's Q3 2024 financial results is furnished as Exhibit 99.1 to this Form 6-K.
What is Evogene Ltd.'s principal executive office address?
Evogene Ltd.'s principal executive office is located at 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel.
Filing Stats: 379 words · 2 min read · ~1 pages · Grade level 10.7 · Accepted 2024-11-21 07:30:21
Filing Documents
- zk2432370.htm (6-K) — 12KB
- exhibit_99-1.htm (EX-99.1) — 555KB
- exhibit_99-2.htm (EX-99.2) — 42KB
- exhibit_99-2slide3.jpg (GRAPHIC) — 118KB
- exhibit_99-2slide7.jpg (GRAPHIC) — 135KB
- exhibit_99-2slide8.jpg (GRAPHIC) — 118KB
- exhibit_99-2slide9.jpg (GRAPHIC) — 179KB
- exhibit_99-2slide11.jpg (GRAPHIC) — 138KB
- exhibit_99-2slide13.jpg (GRAPHIC) — 155KB
- exhibit_99-2slide16.jpg (GRAPHIC) — 127KB
- exhibit_99-2slide17.jpg (GRAPHIC) — 118KB
- exhibit_99-2slide20.jpg (GRAPHIC) — 157KB
- exhibit_99-2slide21.jpg (GRAPHIC) — 158KB
- exhibit_99-2slide22.jpg (GRAPHIC) — 118KB
- exhibit_99-2slide24.jpg (GRAPHIC) — 119KB
- exhibit_99-2slide25.jpg (GRAPHIC) — 119KB
- exhibit_99-2slide26.jpg (GRAPHIC) — 121KB
- exhibit_99-2slide29.jpg (GRAPHIC) — 195KB
- exhibit_99-2slide33.jpg (GRAPHIC) — 297KB
- exhibit_99-2slide36.jpg (GRAPHIC) — 120KB
- exhibit_99-2slide38.jpg (GRAPHIC) — 149KB
- exhibit_99-2slide39.jpg (GRAPHIC) — 174KB
- exhibit_99-2slide40.jpg (GRAPHIC) — 133KB
- exhibit_99-2slide76.jpg (GRAPHIC) — 187KB
- exhibit_99-2slide77.jpg (GRAPHIC) — 228KB
- exhibit_99-2slide86.jpg (GRAPHIC) — 150KB
- exhibit_99-2slide89.jpg (GRAPHIC) — 273KB
- exhibit_99-2slide90.jpg (GRAPHIC) — 288KB
- exhibit_99-2slide99.jpg (GRAPHIC) — 96KB
- 0001178913-24-003796.txt ( ) — 6360KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot Rehovot 7638517, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS On November 21, 2024, Evogene Ltd. (" Evogene ") announced its financial results for the third quarter ended September 30, 2024. A Copy of the press release announcing those results is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this " Form 6-K ") and is incorporated herein by reference. Evogene is holding a conference call on November 21, 2024 to discuss its quarterly results for the quarter ended September 30, 2024 and, in connection with that call, will make available to its investors a slide presentation to provide additional information regarding its business and its financial results. That slide presentation is attached as Exhibit 99.2 to this Form 6-K and is incorporated herein by reference. The GAAP financial statements tables contained in the press release attached as Exhibit 99.1 to this Form 6-K are incorporated by reference in the registration statements on Form F-3 (Securities and Exchange Commission (" SEC ") File No. 333- 277565 ), and Form S-8 (SEC File Nos. 333-193788, 333-201443, 333-203856 and 333-259215 ) of Evogene, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: November 21, 2024 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer EXHIBIT INDEX EXHIBIT NO. DESCRIPTION 99.1 Press Release: Evogene Reports Third Quarter 2024 Financial Results. 99.2 Slide presentation for conference call of Evogene held on November 21, 2024, discussing Evogene's quarterly financial results for the third quarter of 2024.